Skip to content
10-Q

Quarterly Report

ALDEYRA THERAPEUTICS, INC. ALDX

0001341235-26-000006

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 60.32M sh
Shares Diluted Q1 2026 · Mar 31, 2026 60.32M sh
Shares Diluted Q1 2026 · Mar 31, 2025 59.89M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.11M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.47M
Long Term Debt Q1 2026 · Mar 31, 2026 $0
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Short Term Debt Q1 2026 · Mar 31, 2026 $15.3M
Short Term Debt Q1 2026 · Dec 31, 2025 $15.25M
Stockholders Equity Q1 2026 · Mar 31, 2026 $42.16M
Stockholders Equity Q1 2026 · Dec 31, 2025 $44.25M
Stockholders Equity Q1 2026 · Mar 31, 2025 $63.6M
Stockholders Equity Q1 2026 · Dec 31, 2024 $71M
Current Liabilities Q1 2026 · Mar 31, 2026 $24.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $27.81M
Total Liabilities Q1 2026 · Mar 31, 2026 $24.33M
Total Liabilities Q1 2026 · Dec 31, 2025 $27.81M
Current Assets Q1 2026 · Mar 31, 2026 $66.27M
Current Assets Q1 2026 · Dec 31, 2025 $71.78M
Total Assets Q1 2026 · Mar 31, 2026 $66.48M
Total Assets Q1 2026 · Dec 31, 2025 $72.06M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.06
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.17
Eps Basic Q1 2026 · Mar 31, 2026 −$0.06
Eps Basic Q1 2026 · Mar 31, 2025 −$0.17
Sga Expense Q1 2026 · Mar 31, 2026 $1.14M
Sga Expense Q1 2026 · Mar 31, 2025 $3M
Rd Expense Q1 2026 · Mar 31, 2026 $2.41M
Rd Expense Q1 2026 · Mar 31, 2025 $7.42M
Net Income Q1 2026 · Mar 31, 2026 −$3.45M
Net Income Q1 2026 · Mar 31, 2025 −$9.93M
Operating Income Q1 2026 · Mar 31, 2026 −$3.55M
Operating Income Q1 2026 · Mar 31, 2025 −$10.43M